To date, five SGLT2 inhibitors, i.e., dapagliflozin (2008: first published in a journal), canagliflozin (2010), ipragliflozin (2011), tofogliflozin (2012), empagliflozin (2012), and luseogliflozin (2013) have been prescribed for T2D patients. Here, SLC5A2 is linked to type 2 diabetes mellitus.